Cargando…

3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma

BACKGROUND: Bortezomib (BTZ) is an inhibitor of the proteasome that has been used to treat patients with mantle cell lymphoma (MCL), but the resistance to BTZ in clinical cases remains a major drawback. BACH2 is a lymphoid-specific transcription repressor recognized as a tumor suppressor in MCL. Red...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Min, Wang, Jia, Sun, Ming, Li, Guilan, Li, BingXiang, Zhang, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157467/ https://www.ncbi.nlm.nih.gov/pubmed/34039348 http://dx.doi.org/10.1186/s12935-021-01980-2

Ejemplares similares

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
por: Leshchenko, Violetta V., et al.
Publicado: (2015)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
por: Zhao, Ling-Ling, et al.
Publicado: (2015)

The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma
por: Uziel, Orit, et al.
Publicado: (2014)

Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
por: Kim, Areumnuri, et al.
Publicado: (2015)

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
por: Yang, David T, et al.
Publicado: (2008)

Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth
por: Qu, Fu-Lian, et al.
Publicado: (2015)

Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma
por: Chen, Zheng, et al.
Publicado: (2013)

The chemotherapeutic agent bortezomib induces the formation of stress granules
por: Fournier, Marie-Josée, et al.
Publicado: (2010)

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
por: Li, Shi-Jun, et al.
Publicado: (2020)

Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
por: Wong, Kwan Yeung, et al.
Publicado: (2013)

The effectiveness and harms of bortezomib in combination with chemotherapy for mantle cell lymphoma: A protocol for systematic review and meta-analysis
por: Wang, Xiaoxia, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

LncRNA TRG-AS1 stimulates hepatocellular carcinoma progression by sponging miR-4500 to modulate BACH1
por: Sun, Xuehu, et al.
Publicado: (2020)

Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma
por: Quinet, Grégoire, et al.
Publicado: (2022)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

BACH1 mediates the antioxidant properties of aged garlic extract
por: Tsuneyoshi, Tadamitsu
Publicado: (2020)

Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma
por: Luanpitpong, Sudjit, et al.
Publicado: (2022)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
por: Heine, Simon, et al.
Publicado: (2018)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Interfering cellular lactate homeostasis overcomes Taxol resistance of breast cancer cells through the microRNA-124-mediated lactate transporter (MCT1) inhibition
por: Hou, Lu, et al.
Publicado: (2019)

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
por: Rudelius, Martina, et al.
Publicado: (2018)

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
por: Huwyler, Fabrizio, et al.
Publicado: (2023)

CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib
por: Kagiyama, Yuki, et al.
Publicado: (2021)

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
por: Liu, Yang, et al.
Publicado: (2022)

Dual targeting of PI3K and BCL‐2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2022)

Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma
por: Granau, Agnete Marie, et al.
Publicado: (2023)

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
por: Gressin, Rémy, et al.
Publicado: (2019)

Bach
por: Alain, Olivier
Publicado: (1977)

Bach
por: Boyd, Malcolm
Publicado: (1985)

Bach
por: Marcel, Luc-André
Publicado: (1961)

Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells
por: Kim, Yu-Ri, et al.
Publicado: (2014)

Antioxidants stimulate BACH1-dependent tumor angiogenesis
por: Wang, Ting, et al.
Publicado: (2023)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

DNA N(6)-methyladenine modification in hypertension
por: Guo, Ye, et al.
Publicado: (2020)

N6-methyladenine-modified DNA was decreased in Alzheimer’s disease patients
por: Lv, Shuang, et al.
Publicado: (2022)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vjfo7iigip64fg2vg9at9bhfl9